Print

Purpose

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male or female adult ≥ 18 years of age; - Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: - EASI score of 16 or greater, - IGA score of 3 or greater - BSA of 10% or greater,

Exclusion Criteria

  • Subjects with previous exposure to dupilumab. - Known or suspected hypersensitivity to dupilumab or any of its excipients. - History of photosensitivity.

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Dupixent and Narrowband UVB 		Dupixent and Narrowband UVB
  • Drug: Dupixent
    dupilumab 300mg

Recruiting Locations

Eczema Treatment Center of New Jersey
East Windsor, New Jersey 08520
Contact:
Elise Nelson
609-443-4500
enelson@windsordermatology.com

More Details

Status
Recruiting
Sponsor
Psoriasis Treatment Center of Central New Jersey

Study Contact

Elise Nelson
6094434500
enelson@windsordermatology.com

Detailed Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.